<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic juvenile idiopathic arthritis: Course, prognosis, and complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic juvenile idiopathic arthritis: Course, prognosis, and complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic juvenile idiopathic arthritis: Course, prognosis, and complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yukiko Kimura, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marisa Klein-Gitelman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H401605"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Systemic juvenile idiopathic arthritis (formerly called Still's disease or systemic-onset juvenile rheumatoid arthritis [JRA]) is officially a subset of juvenile idiopathic arthritis (JIA), although the pathophysiology is most consistent with an autoinflammatory disorder [<a href="#rid1">1</a>]. Adult-onset Still's disease (AOSD) is probably the same disease when it begins in patients ≥16 years of age. (See  <a class="medical medical_review" href="/d/html/6412.html" rel="external">"Classification of juvenile idiopathic arthritis", section on 'Systemic arthritis'</a>.)</p><p>Children with systemic JIA require close supervision and careful monitoring. Systemic complications, including infections, macrophage activation syndrome (MAS), and pericarditis, are common in this subtype of JIA and are associated with increased morbidity and mortality [<a href="#rid2">2</a>]. Chronic lung disease and other forms of internal organ involvement are less common but are seen with increasing frequency [<a href="#rid3">3-5</a>]. </p><p>The clinical course, prognosis, and complications of systemic JIA are discussed in this review. The clinical manifestations, diagnosis, and treatment of systemic JIA are discussed separately, as are oligoarticular and polyarticular JIA. (See  <a class="medical medical_review" href="/d/html/6413.html" rel="external">"Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment"</a> and  <a class="medical medical_review" href="/d/html/6412.html" rel="external">"Classification of juvenile idiopathic arthritis"</a> and  <a class="medical medical_review" href="/d/html/6415.html" rel="external">"Oligoarticular juvenile idiopathic arthritis"</a> and  <a class="medical medical_review" href="/d/html/6414.html" rel="external">"Polyarticular juvenile idiopathic arthritis: Clinical manifestations, diagnosis, and complications"</a>.)</p><p class="headingAnchor" id="H815997"><span class="h1">COURSE</span><span class="headingEndMark"> — </span>The course of systemic JIA is highly variable, which has prompted many observers to suspect that systemic JIA is not a single entity. The disease course in a typical child with systemic JIA starts with a several-month period of spiking fevers and rash, with varying degrees of arthralgia and arthritis. This may be followed by a relative quiescence of the systemic manifestations. However, there are some children who have persistently active systemic disease, which is associated with worse outcomes [<a href="#rid3">3,6</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p>Generally speaking, there are three disease-course patterns: monophasic, polycyclic, and persistent [<a href="#rid6">6-8</a>]. The actual proportions of systemic JIA patients who follow these disease course patterns are unclear since all studies looking at disease course were single-center studies and the definitions of remission and inactive disease were variable.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monophasic course</strong> – These patients present with active systemic JIA. However, their disease becomes completely quiescent, usually after a period of four to six months, and does not recur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polycyclic course</strong> – These patients have recurrences of active systemic JIA episodes but have long periods of disease inactivity in between. The inactive periods may range from a few months to years. In all series, this is the least common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent course</strong> – These patients (usually the most common course) continue to have a chronic course that can take various forms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic manifestations (ie, fever and rash and sometimes recurrent macrophage activation syndrome [MAS]), but little to no arthritis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent systemic manifestations (sometimes with recurrent MAS) <strong>and</strong> progressive arthritis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent arthritis despite resolution of systemic manifestations. Some of these children have relentless destructive arthritis that progresses despite any therapy and require joint replacements at an early age.</p><p></p><p>Arthritis resolves completely in approximately 40 to 50 percent of patients [<a href="#rid9">9</a>]. The child who appears well after six months has a substantial probability of remaining well, whereas the child who continues to have active disease six months after diagnosis typically has a more difficult and chronic course [<a href="#rid6">6,10,11</a>]. However, some children have recurrences even after years of appearing disease free. Thus, some patients who present with adult-onset Still's disease (AOSD) may, with careful questioning, give a history that suggests that the actual initial onset was in childhood.</p><p class="headingAnchor" id="H1381479707"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Children with systemic JIA who fail to respond adequately to therapy have a significantly poorer prognosis than do children who achieve disease control. In one large, Canadian cohort of children diagnosed with JIA from 2005 to 2010, 71 percent of patients with systemic JIA attained inactive disease within one year, and 47 percent achieved remission within five years [<a href="#rid12">12</a>]. Similar results were seen in a German cohort of patients diagnosed from 2000 to 2013, with 72 percent of patients reported to have inactive disease at three-year follow-up [<a href="#rid13">13</a>]. Retrospective and prospective studies have suggested that there is a "window of opportunity" in which early, effective treatment may greatly improve the chances of remission [<a href="#rid14">14-16</a>]. (See  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment"</a>.)</p><p>In one study that used a "treat to target" approach using <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> in 42 patients with new-onset systemic JIA in a single Dutch center, the rate of inactive disease at one year was 76 percent, with 52 percent of these patients off medication. After five years of follow-up, 75 percent of the patients had inactive disease off medications, potentially supporting the concept of a window of opportunity [<a href="#rid17">17</a>].</p><p>In the past, more than one in three children with systemic JIA developed permanent joint damage [<a href="#rid18">18</a>], with a propensity to affect the hip joint, and more than one-half required substantial prolonged systemic glucocorticoid therapy (often for years) [<a href="#rid19">19</a>]. Patients with active disease (eg, fevers, arthritis, elevated platelet count, continued requirement for glucocorticoid therapy) after the first six months of disease onset have a worse prognosis for continued disease and destructive arthritis [<a href="#rid6">6,10,11</a>]. In addition, one study suggested that children who develop systemic JIA at a very early age, before 18 months of age, may have worse outcomes (arthritis, disability, growth) [<a href="#rid20">20</a>].</p><p>However, significant advances in the treatment of systemic JIA, particularly the use of biologic response modifiers, such as <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> (anti-interleukin [IL] 6 receptor monoclonal antibody), <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> (anti-IL-1-beta monoclonal antibody), and <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> (IL-1 receptor antagonist), are felt to have dramatically improved the prognosis in children with systemic JIA. A study of 372 patients with systemic JIA in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry showed that the overwhelming majority of children with systemic JIA are doing well from a disease activity and disability point of view, but there are children who continue to have significant arthritis despite the use of these biologic agents [<a href="#rid21">21</a>].</p><p>An unusual form of chronic lung disease associated with a poor prognosis is increasingly reported in systemic JIA [<a href="#rid3">3-5</a>]. (See <a class="local">'Lung disease'</a> below.)</p><p class="headingAnchor" id="H816547"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>The overall mortality rate is low in children with systemic JIA, although higher rates are seen in children with more severe disease and in adults with a history of systemic JIA.</p><p>One study examined mortality outcomes in 49,023 pediatric patients diagnosed with a rheumatic disease [<a href="#rid22">22</a>]. The subset of patients with systemic JIA did not have a significantly increased mortality rate, but this study may have missed hospitalized patients at highest risk of mortality. In two clinical trials of systemic JIA patients, there were 3 deaths in 117 patients (2 of which occurred after the trial period) and 4 deaths in 190 patients (2 of which were after the trial period) in the trials of <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> (IL-6 inhibitor) and <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> (IL-1 inhibitor), respectively. These patients mostly had severe, refractory systemic JIA [<a href="#rid23">23,24</a>].</p><p>A high rate of mortality (40 to 60 percent) is also seen in patients with systemic JIA and pulmonary disease [<a href="#rid3">3-5</a>]. One series of 61 patients in 2019 reported a five-year survival rate of 43 percent [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H816554"><span class="h2">Issues in adulthood</span><span class="headingEndMark"> — </span>Adults whose disease began during childhood may have residual problems, including musculoskeletal problems and severe disability. The rates of long-term morbidities are expected to decrease with improvements in therapy, especially if treatment is started early in the disease course [<a href="#rid14">14,16</a>]. (See  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment"</a>.)</p><p>In one study of adults with a history of JIA published in 2002, the mean duration of disease among the 52 patients with systemic JIA was approximately 29 years. The following disease-related features were noted in this cohort of patients whose disease began on average in the 1960s and 1970s, prior to the availability of biologic response modifiers [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Leg-length discrepancies of more than 2 cm were found in 31 percent, possibly related to hip replacement surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restricted jaw opening was present in 54 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe disability, as indicated by Health Assessment Questionnaire (HAQ) scores of 1.5 to 3.0 or by modified Steinbrocker classes of III or IV, was present in 62 and 65 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amyloidosis was present in nearly 20 percent.</p><p></p><p>These results illustrate the importance of effective therapy and the inadequacy of the therapeutic modalities used when these adults were children and developed systemic JIA. These complications are most likely far less frequent with the availability of biologic response modifiers.</p><p class="headingAnchor" id="H816465"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Macrophage activation syndrome (MAS), severe growth retardation, and osteoporosis are the most common complications of systemic JIA and/or its treatment. With more common and earlier usage of biologic response modifiers such as interleukin (IL) 1 and IL-6 inhibitors, complications such as growth retardation and osteoporosis are less likely to occur, but long-term outcomes in the era of biologic treatment still need to be studied. As an example, the actual incidence of lung disease is unknown and should be studied systematically, such as in the context of a large disease registry.</p><p class="headingAnchor" id="H40787333"><span class="h2">Macrophage activation syndrome</span><span class="headingEndMark"> — </span>MAS is a severe complication of systemic JIA that should be treated as a life-threatening emergency [<a href="#rid26">26,27</a>]. The clinical and histopathologic characteristics of MAS are similar to those of hereditary lymphohistiocytic hemophagocytosis (HLH), but the diagnostic criteria for HLH are often not useful to diagnose MAS in systemic JIA. Evidence suggests that there is a shared genetic component in that some patients with systemic JIA and MAS also have protein-altering variants in HLH-associated genes [<a href="#rid28">28</a>]. The specifics of MAS as they relate to systemic JIA are briefly discussed here. This syndrome and its treatment are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Rheumatologic disorders/MAS'</a> and  <a class="medical medical_review" href="/d/html/8384.html" rel="external">"Treatment and prognosis of hemophagocytic lymphohistiocytosis", section on 'MAS/Rheumatologic conditions'</a>.)</p><p class="headingAnchor" id="H931942570"><span class="h3">Clinical presentation</span><span class="headingEndMark"> — </span>MAS typically occurs within the first few days or weeks of the onset of systemic JIA, although it can occur at any point over the course of the disease. Overt MAS occurs in 10 percent of children with systemic JIA but can occur subclinically in another 30 to 40 percent [<a href="#rid29">29</a>]. Some patients have recurrent episodes of MAS. Triggers may include viral or bacterial infections or new medications, but often no inciting event is identified.</p><p>Children may present with spontaneous bleeding, bruising, hepatic dysfunction, lethargy, seizures, coma, or shock. Unremitting fever and rash (unlike the intermittent daily fever and evanescent rash typical of simple active systemic JIA), lymphadenopathy, and hepatosplenomegaly are also common findings. The white blood cell count, hemoglobin, platelet count, and serum fibrinogen typically drop precipitously; liver function tests, triglycerides, and lactate dehydrogenase (LDH) rapidly become elevated; and the ferritin level can climb to well over 1000 ng/mL (often much higher). There is also a paradoxical drop in the erythrocyte sedimentation rate (ESR) due to fibrinogen consumption, which is an important clue [<a href="#rid30">30</a>]. On bone marrow examination, numerous benign macrophages typically exhibit hemophagocytosis, but not all bone marrow specimens from patients with MAS demonstrate this finding and can be normal in appearance.</p><p class="headingAnchor" id="H3859756444"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Early MAS can be difficult to diagnose in the setting of systemic JIA because a systemic disease flare has similar clinical features. In addition, a review of the literature showed that patients who are treated with biologics may have less typical clinical features of MAS that may make it even more challenging to recognize, such as no or lower fever and significantly lower C-reactive protein and ferritin levels in tocilizumab-treated patients [<a href="#rid31">31</a>]. The HLH diagnostic criteria often cannot be applied to MAS in patients with systemic JIA even though the clinical syndromes are similar, because the HLH criteria are too stringent to be able to identify systemic JIA patients in early MAS, when they are most responsive to treatment [<a href="#rid32">32</a>]. Part of the problem lies in the fact that patients with systemic JIA "normally" have highly elevated white blood and platelet counts as well as acute-phase reactants such as the ESR and fibrinogen, so that the initial "normal" levels of these blood tests can be misleading as they are due to declining levels and are actually a signal of impending MAS. As such, there have been many attempts to try to develop clinically useful diagnostic criteria and scoring tools for MAS in systemic JIA patients [<a href="#rid26">26,32,33</a>].</p><p>The differences between the various diagnostic and classification criteria available are shown in the table  (<a class="graphic graphic_table graphicRef121578" href="/d/graphic/121578.html" rel="external">table 1</a>). According to the adapted HLH 2004 guidelines, meeting three of five diagnostic criteria has a sensitivity of 79 percent and specificity of 75 percent to diagnose HLH [<a href="#rid32">32</a>]. The preliminary 2004 MAS in systemic JIA guidelines require that at least two of the laboratory criteria, or three or more of a combination of clinical and/or laboratory criteria, are met. The sensitivity and specificity of these criteria to distinguish between systemic JIA with MAS versus systemic JIA without MAS were both 86 percent [<a href="#rid32">32</a>]. In an attempt to identify more useful criteria, the 2016 classification criteria for MAS in systemic JIA were developed through a combination of expert consensus methods and analysis of real patient data [<a href="#rid33">33</a>]. These require an elevated ferritin and any two of the other criteria.</p><p>A diagnostic scoring tool to differentiate MAS in systemic JIA from active systemic JIA without MAS, called the MAS/sJIA (MS) score, was developed and validated in 2019 [<a href="#rid34">34</a>] using multinational patient data collected for the creation of MAS classification criteria in 2016  (<a class="graphic graphic_table graphicRef130050" href="/d/graphic/130050.html" rel="external">table 2</a>) [<a href="#rid33">33</a>]. Fever is a mandatory criterion for the diagnosis and is not included in the score, although, as stated above, fever may not be present in patients with systemic JIA treated with <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> even when MAS is present. This score still requires validation in clinical practice and may need revisions that take into account the use of biologic agents.</p><p>A diagnostic scoring tool to help distinguish HLH from MAS in systemic JIA based upon a few clinical parameters, called the MH (MAS-HLH) score, is also available  (<a class="graphic graphic_table graphicRef121579" href="/d/graphic/121579.html" rel="external">table 3</a>) [<a href="#rid35">35</a>]. This score was validated using data from a large, multinational, retrospectively collected cohort of patients with systemic JIA and MAS compared with data from clinical trials of genetically confirmed patients with HLH. This tool was able to distinguish these two illnesses with high specificity and sensitivity. The MH score assigns points for age at onset, neutrophil count, fibrinogen, splenomegaly, platelet count, and hemoglobin. Having an age less than or equal to 1.6 years at onset and a neutrophil count less than or equal to 1.4 x 10<sup>9</sup>/L were the most important factors in favor of a diagnosis of HLH rather than MAS complicating systemic JIA.</p><p class="headingAnchor" id="H4241265830"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Once MAS is diagnosed or suspected, treatment of MAS should be emergently initiated with high-dose glucocorticoids (most often "pulse" <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> at 30 mg/kg, maximum dose 1 gram, intravenously daily) [<a href="#rid30">30</a>]. There are case reports of successful treatment with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, or <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>, an IL-1 receptor antagonist [<a href="#rid3">3,27,36,37</a>]. Treatment for refractory MAS in patients with systemic JIA is the same as treatment regimens for HLH, which are discussed separately. (See  <a class="medical medical_review" href="/d/html/8384.html" rel="external">"Treatment and prognosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p class="headingAnchor" id="H2861691547"><span class="h2">Lung disease</span><span class="headingEndMark"> — </span>An unusual form of incompletely defined and characterized chronic lung disease with a high fatality rate is increasingly seen [<a href="#rid3">3-5</a>]. The reasons for the increased frequency of lung disease are unclear, although there is a temporal association coincident with the more common usage of biologic response modifiers in systemic JIA. Typically, these patients have severe systemic disease that is difficult to control, many with features of MAS (acute and chronic). Acute erythematous clubbing is an early physical sign in many patients, and it is associated with anaphylactic reactions to <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, younger age at onset, and trisomy 21 [<a href="#rid4">4</a>]. The pathology of lung disease in systemic JIA is also unusual, with pulmonary alveolar proteinosis (PAP) and/or endogenous lipoid pneumonia (ELP) predominant. Septal thickening of peripheral lobes with ground glass opacities are the most common lung computed tomography (CT) findings. Higher levels of IL-18 were seen in the serum of these patients as well as in the bronchoalveolar lavage (BAL) fluid, which also contained high levels of the interferon gamma-induced chemokine (C-X-C motif) ligands (CXCL) 9 and 10 [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H401617"><span class="h2">Growth retardation</span><span class="headingEndMark"> — </span>Profound growth abnormalities with obesity and short stature were common complications of disease when glucocorticoids were one of the primary treatments of systemic JIA. They resulted both from glucocorticoid side effects of the therapy and from incomplete suppression of systemic inflammation. These complications are less frequent due to the availability of safer and more effective therapies that allow more judicious use of glucocorticoids [<a href="#rid38">38</a>]. Short stature and failure to thrive may still be seen, however, in those with chronic unremitting disease, even in those who do not receive glucocorticoids [<a href="#rid39">39-41</a>].</p><p class="headingAnchor" id="H401623"><span class="h2">Osteoporosis</span><span class="headingEndMark"> — </span>Osteoporosis in children with systemic JIA was also more common prior to advances in treatment. Measures used in adults to treat osteoporosis are frequently ineffective or are poorly tolerated in children with systemic JIA. The optimal way to minimize this complication is to attain disease control with a minimum of glucocorticoid exposure, which was not often possible in the pre-biologic era. Minimizing glucocorticoid administration is the best way to avoid both growth retardation and osteoporosis. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Bone and muscle effects'</a>.)</p><p>Bisphosphonates may be an option for treating children with JIA and severe osteoporosis and may be necessary to prevent recurrent insufficiency fractures in severely affected patients, but the safety of bisphosphonate use by children remains uncertain. Excessive amounts can lead to osteopetrosis. The decision to use bisphosphonates must be made on a case-by-case basis since these medications may be teratogenic and have a long half-life, stored in and slowly released from the bone for years [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H816152"><span class="h2">Other complications</span><span class="headingEndMark"> — </span>A few cases of atypical renal, cardiac, hepatic, endocrine, or other complications have been reported in every large series, but the extent to which these represent incidental findings or complications of systemic JIA is uncertain [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1255711936"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112604.html" rel="external">"Society guideline links: Juvenile idiopathic arthritis"</a>.)</p><p class="headingAnchor" id="H3173744"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course</strong> – The course of systemic juvenile idiopathic arthritis (JIA) is highly variable, although there are three typical patterns: monophasic, polycyclic, and persistent (chronic). (See <a class="local">'Course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patterns of chronic disease activity</strong> – Three patterns of chronic disease activity occur in those patients with persistent systemic JIA (see <a class="local">'Course'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic manifestations (ie, fever and rash and sometimes recurrent macrophage activation syndrome [MAS]), but little to no arthritis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent systemic manifestations and progressive arthritis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progressive destructive arthritis despite resolution of systemic manifestations</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Morbidity and mortality from systemic JIA have decreased with improvements in therapy, but mortality is still high in patients with severe disease, especially those with recurrent or unrecognized MAS and severe pulmonary or vascular complications. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – MAS is the most common complication of systemic JIA. Complications such as severe growth retardation and osteoporosis are now less frequent. There is a rising incidence of rare but severe pulmonary complications. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="headingAnchor" id="H32064059"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Thomas JA Lehman, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31:390.</a></li><li class="breakAll">De Benedetti F, Schneider R. Systemic juvenile idiopathic arthritis. In: Textbook of Pediatric Rheumatology, 7th ed, Petty RE, Laxer RM, Lindsley CB, Wedderburn LR (Eds), Elsevier, Philadelphia 2016. p.205.</li><li><a class="nounderline abstract_t">Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013; 65:745.</a></li><li><a class="nounderline abstract_t">Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 2019; 78:1722.</a></li><li><a class="nounderline abstract_t">Schulert GS, Yasin S, Carey B, et al. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol 2019; 71:1943.</a></li><li><a class="nounderline abstract_t">Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006; 54:1595.</a></li><li><a class="nounderline abstract_t">Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000; 27:491.</a></li><li><a class="nounderline abstract_t">Fantini F, Gerloni V, Gattinara M, et al. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003; 30:579.</a></li><li><a class="nounderline abstract_t">Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46:2392.</a></li><li><a class="nounderline abstract_t">Schneider R, Lang BA, Reilly BJ, et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr 1992; 120:200.</a></li><li><a class="nounderline abstract_t">Spiegel LR, Schneider R, Lang BA, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000; 43:2402.</a></li><li><a class="nounderline abstract_t">Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015; 74:1854.</a></li><li><a class="nounderline abstract_t">Klotsche J, Raab A, Niewerth M, et al. Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013. Arthritis Rheumatol 2016; 68:3023.</a></li><li><a class="nounderline abstract_t">Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 2014; 66:1405.</a></li><li><a class="nounderline abstract_t">Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63:545.</a></li><li><a class="nounderline abstract_t">Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014; 66:1034.</a></li><li><a class="nounderline abstract_t">Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol 2019; 71:1163.</a></li><li><a class="nounderline abstract_t">Oen K, Malleson PN, Cabral DA, et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29:1989.</a></li><li><a class="nounderline abstract_t">Svantesson H, Akesson A, Eberhardt K, Elborgh R. Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study. Scand J Rheumatol 1983; 12:139.</a></li><li><a class="nounderline abstract_t">Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol 2013; 40:329.</a></li><li><a class="nounderline abstract_t">Janow G, Schanberg LE, Setoguchi S, et al. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. J Rheumatol 2016; 43:1755.</a></li><li><a class="nounderline abstract_t">Hashkes PJ, Wright BM, Lauer MS, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010; 62:599.</a></li><li><a class="nounderline abstract_t">De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2385.</a></li><li><a class="nounderline abstract_t">Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2396.</a></li><li><a class="nounderline abstract_t">Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002; 41:1428.</a></li><li><a class="nounderline abstract_t">Davì S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38:764.</a></li><li><a class="nounderline abstract_t">Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012; 13:289.</a></li><li><a class="nounderline abstract_t">Kaufman KM, Linghu B, Szustakowski JD, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2014; 66:3486.</a></li><li><a class="nounderline abstract_t">Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133.</a></li><li><a class="nounderline abstract_t">Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014; 66:3160.</a></li><li><a class="nounderline abstract_t">Schulert GS, Minoia F, Bohnsack J, et al. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken) 2018; 70:409.</a></li><li><a class="nounderline abstract_t">Davì S, Minoia F, Pistorio A, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66:2871.</a></li><li><a class="nounderline abstract_t">Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 2016; 68:566.</a></li><li><a class="nounderline abstract_t">Minoia F, Bovis F, Davì S, et al. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis 2019; 78:1357.</a></li><li><a class="nounderline abstract_t">Minoia F, Bovis F, Davì S, et al. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. J Pediatr 2017; 189:72.</a></li><li><a class="nounderline abstract_t">Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011; 17:23.</a></li><li><a class="nounderline abstract_t">Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med 2014; 15:401.</a></li><li><a class="nounderline abstract_t">Guzman J, Kerr T, Ward LM, et al. Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatr Rheumatol Online J 2017; 15:68.</a></li><li><a class="nounderline abstract_t">Polito C, Strano CG, Olivieri AN, et al. Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol 1997; 26:99.</a></li><li><a class="nounderline abstract_t">Aggarwal B, Bhalla AK, Singh S. Longitudinal growth attainments of Indian boys with juvenile rheumatoid arthritis. Rheumatol Int 2011; 31:635.</a></li><li><a class="nounderline abstract_t">Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 2009; 72 Suppl 1:20.</a></li><li class="breakAll">Cimaz R, Ward L. The impact of rheumatic diseases and their treatment on bone strength development in childhood. In: Textbook of Pediatric Rheumatology, 7th ed, Petty R, Laxer R, Lindsley C, Wedderburn L (Eds), Elsevier Saunders, Philadelphia 2016. p.693.</li></ol></div><div id="topicVersionRevision">Topic 13512 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760812" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760812" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23139240" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562126" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Emergent high fatality lung disease in systemic juvenile arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31379071" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645998" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10685819" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610820" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355487" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term outcome in patients with juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735815" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083261" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842571" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27332999" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623686" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21280009" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24757154" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30848528" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233897" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6857171" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23322471" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27307527" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20112378" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mortality outcomes in pediatric rheumatology in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252525" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252526" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468825" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285158" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22418018" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25047945" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17343315" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25077692" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28499329" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25044674" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26314788" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31296501" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28807357" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169853" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24583503" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28830457" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9137323" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Growth retardation in non-steroid treated juvenile rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20054693" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Longitudinal growth attainments of Indian boys with juvenile rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940491" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adult outcomes of patients with juvenile idiopathic arthritis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
